3,4-二氯-5-甲基苯酚 | 94705-20-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-二氯-5-甲基苯酚
• 英文名称: 3,4-Dichloro-5-methylphenol
• CAS: 94705-20-1
• 化学式: C₇H₆Cl₂O
• 分子量: 177.02
• InChiKey: FVRLJMQDXQTHFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Process for the synthesis of phenols from arenes
  申请人：Board of Trustees of Michigan State University

  公开号：US20040030197A1

  公开（公告）日：2004-02-12

  A process to synthesize substituted phenols such as those of the general formula RR′R″Ar(OH) wherein R, R′, and R″ are each independently hydrogen or any group which does not interfere in the process for synthesizing the substituted phenol including, but not limited to, halo, alkyl, alkoxy, carboxylic ester, amine, amide; and Ar is any variety of aryl or hetroaryl by means of oxidation of substituted arylboronic esters is described. In particular, a metal-catalyzed C—H activation/borylation reaction is described, which when followed by direct oxidation in a single or separate reaction vessel affords phenols without the need for any intermediate manipulations. More particularly, a process wherein Ir-catalyzed borylation of arenes using pinacolborane (HBPin) followed by oxidation of the intermediate arylboronic ester by OXONE is described.

  描述了一种合成取代酚的过程，如通式RR′R″Ar(OH)中的那些，其中R、R′和R″分别独立地是氢或不干扰合成取代酚过程的任何基团，包括但不限于卤素、烷基、烷氧基、羧酸酯、胺、酰胺；Ar是芳基或杂芳基的任何种类，通过氧化取代芳基硼酸酯来实现。具体地，描述了一种金属催化的C—H活化/硼化反应，随后在单个或分离的反应容器中直接氧化，从而获得酚，无需任何中间操作。更具体地，描述了一种通过Ir催化的芳烃硼化反应，使用二醇硼烷（HBPin）后，通过OXONE氧化中间芳基硼酸酯的过程。
• FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD

  公开号：US20220389029A1

  公开（公告）日：2022-12-08

  Disclosed in the present invention are a fused pyridone compound, and a preparation method therefor and a use thereof. Specifically, the present invention discloses a compound of formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.

  本发明公开了一种融合吡啶酮化合物及其制备方法和用途。具体地，本发明公开了一种I-B式化合物，其光学异构体和药学上可接受的盐，并将该化合物用作KRAS抑制剂。
• Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0126449A1

  公开（公告）日：1984-11-28

  Novel compounds of the general formula and the pharmaceutically acceptable esters and acid addition salts thereof, wherein: R1, R2, R3, R4, and R5 are each independently hydrogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, N-optionally substituted alkylamido, except that when R1 is methyl, R4 is not methyl; or R2 and R3 together form -OCH2O-; R6, R7, R8, R9 and R10 are each independently hydrogen, lower acyl, aminocarbonyl-methyl, arylcyano, lower alkyl, lower alkoxy, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, di-lower alkyl amino; or R6 and R7 together form -CH = CH-CH = CH-; R7 and R8 together form -OCH2O -; R11 and R12 are each independently hydrogen or lower alkyl; and W is oxygen or sulfur. These cardioselective compounds have calcium entry blockade properties and therefore are useful in therapy in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise induced angina and myocardial infarction.

  通式为 及其药学上可接受的酯和酸加成盐，其中 R1、R2、R3、R4 和 R5 各自独立地为氢、低级烷基、低级烷氧基、氰基、三氟甲基、卤代、低级烷硫基、低级烷基亚磺酰基、低级烷基磺酰基、N-可选取代的烷基氨基，但当 R1 为甲基时，R4 不是甲基；或 R2 和 R3 共同形成 -OCH2O-； R6、R7、R8、R9 和 R10 各自独立地为氢、低级酰基、氨基羰基甲基、芳基氰基、低级烷基、低级烷氧基、三氟甲基、卤代、低级烷硫基、低级烷基亚磺酰基、低级烷基磺酰基、二低级烷基氨基；或 R6 和 R7 共同形成 -CH = CH-CH = CH-； R7 和 R8 共同形成 -OCH2O -； R11 和 R12 各自独立地为氢或低级烷基；以及 W 是氧或硫。 这些心脏选择性化合物具有钙离子进入阻断特性，因此可用于治疗心血管疾病，包括心律失常、变异型和运动诱发的心绞痛和心肌梗塞。
• KRAS G12C inhibitors and methods of using the same
  申请人：Amgen Inc.

  公开号：US10519146B2

  公开（公告）日：2019-12-31

  Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供了 KRAS G12C 抑制剂、其组合物以及使用方法。这些抑制剂可用于治疗多种疾病，包括胰腺癌、结直肠癌和肺癌。
• [EN] FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] COMPOSÉ DE PYRIDONE FUSIONNÉE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 稠合吡啶酮类化合物及其制备方法和应用
  申请人：SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD

  公开号：WO2021052499A1

  公开（公告）日：2021-03-25

  本发明公开了稠合吡啶酮类化合物及其制备方法和应用，具体地，本发明公开了式(I-B)所示化合物、其光学异构体及其药效上可接受的盐，以及该化合物作为KRAS抑制剂的应用。